Arrowhead Pharmaceuticals

RNAi therapeutics

ARWR · Nasdaq · United States

Share price · ARWR

$43.11-44.79 (-50.96%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.4M (1.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ARWR's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 9 Nov 2026-15.3%
  2. 15 Sep 2026-12.4%
  3. 22 Jul 2026+19.0%
  4. 10 Jul 2026-9.0%
  5. 11 May 2026+6.9%
  6. 8 May 2026-6.7%
  7. 15 Apr 2026+6.4%
  8. 7 Jan 2026-7.2%
  9. 6 Jan 2026+10.8%
  10. 8 Dec 2025+11.7%

Share of unusual movement by asset

For each asset, the share of ARWR's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Plozasiran (Redemplo)
events and moves
1517%
ARO-MAPT-SC
events and moves
3shown from 8 days
ARO-DIMER-PA
events and moves
2shown from 8 days
ARO-INHBE
events and moves
1shown from 8 days
Zodasiran
events and moves
1shown from 8 days
ARO-C3
events and moves
1shown from 8 days
SRP-1001
events and moves
1shown from 8 days
SRP-1003
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—4%
Other company news (earnings, financing, releases naming no asset)—34%
Sessions with no dated event—46%

Assets

(16 total)
16Total Assets
1Approved
3Phase 3 / Filed
12Phase 1–2 / Early
16Diseases
Quick filter:
Showing 16 of 16 assets
Target & Modality
Plozasiran(Redemplo)
Approved
APOC3RNA / oligonucleotide
Familial Chylomicronemia SyndromeSevere HypertriglyceridemiaCardiovascular Disease / Dyslipidemia
Hypertriglyceridemia
Phase 3
SERPINA1RNA / oligonucleotide
Alpha-1 Antitrypsin Deficiency
Phase 3
LPA gene / apolipoprotein(a) mRNARNA / oligonucleotide
Atherosclerotic Cardiovascular Disease
Phase 3
ANGPTL3 gene mRNA (hepatic)RNA / oligonucleotide
Homozygous Familial Hypercholesterolemia
Phase 2
RAGE (receptor for advanced glycation end-products)RNA / oligonucleotide
Asthma
Phase 2
HBV RNA (X and S transcripts)RNA / oligonucleotide
Chronic Hepatitis B
Phase 2
HSD17B13RNA / oligonucleotide
MASH / NASH
Phase 1/2
ALK7 (Activin receptor-like kinase 7)RNA / oligonucleotide
Obesity
Phase 1/2
Complement C3RNA / oligonucleotide
Complement-Mediated Renal Disease
Phase 1/2
PCSK9/APOC3RNA / oligonucleotide
Mixed Hyperlipidemia
Phase 1/2
INHBE (Inhibin beta E chain / Activin E)RNA / oligonucleotide
Obesity
Phase 1/2
MAPT mRNA (RNAi/ASO)RNA / oligonucleotide
Alzheimer's Disease
Phase 1/2
DUX4RNA / oligonucleotide
Facioscapulohumeral Muscular Dystrophy
Phase 1/2
DMPK (dystrophia myotonica protein kinase)RNA / oligonucleotide
Myotonic Dystrophy Type 1
Phase 1
Complement factor B (CFB) mRNARNA / oligonucleotide
IgA Nephropathy

Upcoming events

(20 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
SRP-1003Phase 1/2Myotonic Dystrophy 1
Est. primary completion 2026-12-31 · NCT06138743 · CT.gov ↗
What to watch
2027 (8)
February 2027 (1)
ARO-ALK7Phase 1/2Obesity, Diabetes Mellitus, Type 2
Est. primary completion 2027-02 · NCT06937203 · CT.gov ↗
What to watch
May 2027 (1)
Daplusiran/TomligisiranPhase 2Chronic Hepatitis B Virus Infection, Hepatitis B
Est. primary completion 2027-05-31 · NCT06537414 · CT.gov ↗
What to watch
June 2027 (1)
ARO-MAPT-SCPhase 1/2Alzheimer Disease, Tauopathies, Frontotemporal Dementia, Progressive Supranuclear Palsy
Est. primary completion 2027-06 · NCT07221344 · CT.gov ↗
What to watch
July 2027 (1)
ARO-DIMER-PAPhase 1/2Hyperlipidemia; Mixed
Est. primary completion 2027-07 · NCT07223658 · CT.gov ↗
What to watch
August 2027 (1)
ZodasiranPhase 3Homozygous Familial Hypercholesterolemia
Est. primary completion 2027-08-20 · NCT07037771 · CT.gov ↗
What to watch
October 2027 (1)
ARO-INHBEPhase 1/2Obesity
Est. primary completion 2027-10-15 · NCT06700538 · CT.gov ↗
What to watch
November 2027 (1)
GatuzosiranPhase 2Liver Diseases, Alcoholic
Est. primary completion 2027-11-26 · NCT06613698 · CT.gov ↗
What to watch
December 2027 (1)
ARO-RAGEPhase 2Asthma
Est. primary completion 2027-12 · NCT07241546 · CT.gov ↗
What to watch
2028 (6)
March 2028 (1)
OlpasiranPhase 3Atherosclerotic Cardiovascular Disease
Est. primary completion 2028-03-31 · NCT05581303 · CT.gov ↗
What to watch
June 2028 (1)
OlpasiranPhase 3Cardiovascular Disease
Est. primary completion 2028-06-15 · NCT07293260 · CT.gov ↗
What to watch
July 2028 (2)
Plozasiran · RedemploPhase 3Hypertriglyceridemia
Est. primary completion 2028-07 · NCT06822790 · CT.gov ↗
What to watch
ZodasiranPhase 3Homozygous Familial Hypercholesterolemia
Est. primary completion 2028-07 · NCT07473843 · CT.gov ↗
What to watch
August 2028 (1)
FazirsiranPhase 3Alpha1-Antitrypsin Deficiency
Est. primary completion 2028-08-26 · NCT06165341 · CT.gov ↗
What to watch
December 2028 (1)
SRP-1001Phase 1/2Muscular Dystrophy, Facioscapulohumeral
Est. primary completion 2028-12-31 · NCT06131983 · CT.gov ↗
What to watch
2029 (3)
January 2029 (1)
FazirsiranPhase 3Alpha1-Antitrypsin Deficiency
Est. primary completion 2029-01-17 · NCT05677971 · CT.gov ↗
What to watch
March 2029 (1)
Plozasiran · RedemploPhase 3Severe Hypertriglyceridemia
Est. primary completion 2029-03 · NCT06880770 · CT.gov ↗
What to watch
October 2029 (1)
ARO-INHBEPhase 2Metabolic Dysfunction-Associated Steatohepatitis
Est. primary completion 2029-10 · NCT07859813 · CT.gov ↗
What to watch
2031 (1)
October 2031 (1)
OlpasiranPhase 3Cardiovascular Disease
Est. primary completion 2031-10-20 · NCT07136012 · CT.gov ↗
What to watch
2033 (1)
May 2033 (1)
FazirsiranPhase 3Alpha1-Antitrypsin Deficiency
Est. primary completion 2033-05-02 · NCT05899673 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(8)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

22 July 2026Topline resultPlozasiranSHASTA-3 and SHASTA-4 topline: primary endpoint met
Arrowhead Pharmaceuticals · Source ↗
22 June 2026ApprovalPlozasiranEC grants marketing authorization for REDEMPLO in FCS
EU, EMA · Source ↗
1 May 2026ApprovalPlozasiranTGA approves REDEMPLO (plozasiran) for FCS in Australia
AU, TGA · Source ↗
25 March 2026Topline resultSRP-1001First-in-human SRP-1001 data: muscle delivery and creatine kinase reduction
7 January 2026ApprovalPlozasiranNMPA approves REDEMPLO for FCS in China
CN, NMPA · Source ↗
5 January 2026ApprovalPlozasiranHealth Canada approves REDEMPLO (plozasiran) for FCS
CA, Health Canada · Source ↗
18 November 2025ApprovalPlozasiranFDA approves REDEMPLO (plozasiran) for FCS
US, FDA · Source ↗
10 March 2025Topline resultARO-C3ARO-C3 Phase 1/2 Part 2 topline results in IgA nephropathy
Arrowhead Pharmaceuticals · Source ↗

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$75M—$55M+ $1.5B short-term inv.$194M-$177M operating cash flowreport ↗

Arrowhead Pharmaceuticals reported revenue of $75.25M for the quarter ended June 30, 2026, up 171.0% YoY from $27.77M. R&D spend was not disclosed; cash and equivalents were $54.76M. The company recorded a net loss of $194.28M, equal to its quarterly net burn of $194.28M.

Key developments included continued U.S. commercial momentum for REDEMPLO, with new marketing authorizations from the European Commission and the Australian TGA for familial chylomicronemia syndrome. Topline results from the Phase 3 SHASTA-3 and SHASTA-4 trials of plozasiran met their primary and all prespecified secondary endpoints, including a 78% reduction in acute pancreatitis events; detailed results are scheduled for ESC 2026. Enrollment completed in the Phase 3 YOSEMITE trial of zodasiran, with study completion anticipated in mid-2027. The company also licensed ARO-PNPLA3 to Madrigal Pharmaceuticals for up to $975M in milestones and acquired an FDA priority review voucher for a planned plozasiran sNDA.

View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$74M—$189M+ $1.6B short-term inv.$133M$84M operating cash flowreport ↗
2025-Q4$264M—$202M+ $715M short-term inv.—$13M operating cash flowreport ↗
2025-Q2$28M$162M$130M+ $771M short-term inv.$175M-$155M operating cash flowreport ↗
2025-Q1$543M$133M$186M+ $912M short-term inv.—$460M operating cash flowreport ↗
2024-Q4$2.5M$137M$54M+ $499M short-term inv.$173M-$146M operating cash flowreport ↗
2024-Q2$0$152M$69M+ $367M short-term inv.$171M-$115M operating cash flowreport ↗
2024-Q1$0$101M$128M+ $395M short-term inv.$125M-$92M operating cash flowreport ↗
2023-Q4$3.5M$116M$58M+ $162M short-term inv.$133M-$118M operating cash flowreport ↗
2023-Q2$16M$95M$105M$103M-$21M operating cash flowreport ↗
2023-Q1$146M$75M$135M—-$32M operating cash flowreport ↗
2022-Q4$63M$84M$202M$41M-$76M operating cash flowreport ↗
2022-Q2$32M$72M—+ $0 short-term inv.$72M-$69M operating cash flowreport ↗
2022-Q1$152M$76M—+ $123M short-term inv.—$63M operating cash flowreport ↗
2021-Q4$27M$66M—+ $126M short-term inv.$63M-$61M operating cash flowreport ↗

Annual history (6 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-FY$451M$739M$63M+ $1.1B short-term inv.$181M-$272M operating cash flowreport ↗
View 5 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$829M—$227M+ $693M short-term inv.$0.4M$180M operating cash flowreport ↗
2024-FY$3.5M$506M$103M+ $578M short-term inv.$150M-$463M operating cash flowreport ↗
2023-FY$241M$353M$111M+ $293M short-term inv.$51M-$154M operating cash flowreport ↗
2022-FY$243M$297M$108M+ $0 short-term inv.$44M-$136M operating cash flowreport ↗
2021-FY$138M$206M$184M+ $127M short-term inv.$35M$171M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 64 sales ($37.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-08-18PERRY MICHAEL S · directorOpen-market sale11,600$87.30$1.0MForm 4
2026-08-18OLUKOTUN ADEOYE Y · directorOpen-market sale2,000$86.96$174KForm 4
2026-06-15Cohen Matthew Gregory · directorAward / grant11,882——Form 4
2026-05-12Lu Hongbo · directorOpen-market sale2,970$76.88$228KForm 4
2026-04-23Hamilton James C · Chief Medical OfficerOpen-market sale10,000$75.00$750KForm 4
2026-04-22Apel Daniel Joseph · Chief Financial OfficerOpen-market sale3,208$70.11$225KForm 4
2026-04-22Apel Daniel Joseph · Chief Financial OfficerOpen-market sale1,157$70.45$82KForm 4
2026-04-22Apel Daniel Joseph · Chief Financial OfficerOpen-market sale8,730$71.92$628KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 431 reporting institutions held 120.7M shares ($7.4B, 85.4% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.18,161,519$1.1B
2Avoro Capital Advisors LLC10,699,999$670.9M
3FMR LLC7,266,652$455.6M
4VANGUARD PORTFOLIO MANAGEMENT LLC7,146,136$448.1M
5STATE STREET CORP6,496,130$407.3M
6VANGUARD CAPITAL MANAGEMENT LLC6,032,416$378.2M
7GEODE CAPITAL MANAGEMENT, LLC4,278,828$274.5M
8FRED ALGER MANAGEMENT, LLC3,342,493$209.6M
9Invesco Ltd.3,280,647$205.7M
10Vestal Point Capital, LP2,275,000$142.6M
11BAKER BROS. ADVISORS LP1,992,783$124.9M
12GOLDMAN SACHS GROUP INC1,739,923$109.1M
13NORTHERN TRUST CORP1,655,837$103.8M
14Siren, L.L.C.1,615,476$101.3M
15DEERFIELD MANAGEMENT COMPANY, L.P.1,573,297$98.6M